Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.
- 25 August 1999
- journal article
- controversies
- Published by American Medical Association (AMA) in JAMA
- Vol. 282 (8), 786-790
- https://doi.org/10.1001/jama.282.8.786
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Does Hyperglycemia Really Cause Coronary Heart Disease?Diabetes Care, 1997
- Valvular Heart Disease Associated with Fenfluramine–PhentermineNew England Journal of Medicine, 1997
- Surrogates, Semantics, and Sensible Public PolicyCirculation, 1997
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Appetite-Suppressant Drugs and the Risk of Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes MellitusAnnals of Internal Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Research and Clinical Practice, 1995
- Cholesterol Reduction Yields Clinical BenefitCirculation, 1995
- Role of surrogate end points in the evaluation of drugs for heart failureJournal of the American College of Cardiology, 1993